SCHEDULE 13G/A: Biotechnology Value Fund Entities Disclose Significant 9.9% Stake in Septerna, Inc.

Multiple entities associated with Biotechnology Value Fund, including BVF Partners L.P. and Mark N. Lampert, have disclosed a combined beneficial ownership of 9.9% of Septerna, Inc.'s common stock as of March 31, 2025.

Summary

• Biotechnology Value Fund, L.P. (BVF) beneficially owns 2,299,671 shares, representing approximately 5.2% of Septerna, Inc.'s outstanding common stock.
• Biotechnology Value Fund II, L.P. (BVF2) beneficially owns 1,804,322 shares, representing approximately 4.1% of Septerna, Inc.'s outstanding common stock.
• Biotechnology Value Trading Fund OS LP beneficially owns 233,426 shares, representing less than 1% of Septerna, Inc.'s outstanding common stock.
• BVF GP Holdings LLC, as the sole member of BVF I GP LLC and BVF II GP LLC, is deemed to beneficially own 4,103,993 shares, or approximately 9.2% of the outstanding shares.
• BVF Partners L.P., as the investment manager, and BVF Inc., as its general partner, along with Mark N. Lampert, are deemed to beneficially own an aggregate of 4,396,124 shares, representing approximately 9.9% of Septerna, Inc.'s outstanding common stock.
• The percentages are based on 44,442,496 shares outstanding as of March 17, 2025, as reported in Septerna, Inc.'s Annual Report on Form 10-K filed on March 27, 2025.
• The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.9% stake by a reputable biotechnology-focused investment group like Biotechnology Value Fund is generally viewed positively by the market, indicating institutional confidence in the company. The filing itself is a routine disclosure, but the size of the stake is notable.

Positives

• A significant stake by a specialized biotechnology investment fund like Biotechnology Value Fund could signal confidence in Septerna, Inc.'s long-term prospects and strategic direction.
• The aggregation of shares across multiple funds managed by BVF Partners L.P. indicates a coordinated investment strategy.

Negatives

• The filing itself does not contain negative information; it is a disclosure of ownership.

Risks

• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing control, which mitigates immediate activist investor concerns, but the large stake could still lead to future engagement or influence on corporate governance, particularly concerning nominations under Rule 14a-11.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Septerna, Inc. or the reporting entities regarding the issuer's future performance.

Industry Context

This filing indicates a significant investment by a specialized biotechnology fund in Septerna, Inc., a company operating within the biotechnology sector. Such investments are common as funds seek to capitalize on growth opportunities in innovative drug development and life sciences. The fund's focus on biotechnology suggests a strategic alignment with Septerna's business model and potential for future value creation within the industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by a specialized fund may be perceived positively, potentially increasing investor confidence and attracting further institutional interest. It also indicates a large block of shares held by a single group, which could influence voting matters.
• Company Management: Management will be aware of a significant shareholder group, which may lead to increased engagement or scrutiny regarding strategic decisions and corporate performance.

Key Dates

Keywords

Beneficial Ownership, SEC Filing, Schedule 13G, Septerna Inc., Biotechnology Value Fund, Investment Fund, Common Stock, Institutional Ownership, Equity Stake, Biotechnology